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Abstract. 
 
The Fas/APO-1/CD95 ligand (CD95L) and 
the recently cloned TRAIL ligand belong to the TNF-
family and share the ability to induce apoptosis in sensi-
tive target cells. Little information is available on the 
degree of functional redundancy between these two 
ligands in terms of target selectivity and intracellular 
signalling pathway(s). To address these issues, we have 
expressed and characterized recombinant mouse 
TRAIL. Specific detection with newly developed rabbit 
anti-TRAIL antibodies showed that the functional 
TRAIL molecule released into the supernatant of re-
combinant baculovirus-infected Sf9 cells is very similar 
to that associated with the membrane fraction of Sf9 
cells. CD95L resistant myeloma cells were found to be 
sensitive to TRAIL, displaying apoptotic features simi-
lar to those of the CD95L- and TRAIL-sensitive T leu-
kemia cells Jurkat. To assess if IL-1
 
b
 
-converting en-
zyme (ICE) and/or ICE-related proteases (IRPs) 
(caspases) are involved in TRAIL-induced apoptosis of 
both cell types, peptide inhibition experiments were 
performed. The irreversible IRP/caspase-inhibitor Ac-
YVAD-cmk and the reversible IRP/caspase-inhibitor 
Ac-DEVD-CHO blocked the morphological changes, 
disorganization of plasma membrane phospholipids, 
DNA fragmentation, and loss of cell viability associated 
with TRAIL-induced apoptosis. In addition, cells un-
dergoing TRAIL-mediated apoptosis displayed cleav-
age of poly(ADP)-ribose polymerase (PARP) that was 
completely blocked by Ac-DEVD-CHO.
These results indicate that TRAIL seems to comple-
ment the activity of the CD95 system as it allows cells, 
otherwise resistant, to undergo apoptosis triggered by 
specific extracellular ligands. Conversely, however, in-
duction of apoptosis in sensitive cells by TRAIL in-
volves IRPs/caspases in a fashion similar to CD95L. 
Thus, differential sensitivity to CD95L and TRAIL 
seems to map to the proximal signaling events associ-
ated with receptor triggering.
 
R
 
ecently
 
, a new member of the TNF family, the
TRAIL/APO-2 ligand has been cloned and shown
to induce apoptosis in sensitive target cells (Wiley
et al., 1995; Pitti et al., 1996). Within the TNF family, hu-
man TRAIL shares the highest similarity (28% homology
at the amino acid level) with CD95L.
The FAS/APO-1/CD95 ligand (CD95L)
 
1
 
 (Suda et al.,
1993; Suda and Nagata, 1994) is a member of the TNF
family, that induces apoptosis in sensitive target cells (for
review see Krammer et al., 1994; Nagata and Golstein,
1995). Highly expressed by activated T cells, CD95L has
been shown to mediate T cell cytotoxicity (Kägi et al.,
1994; Lowin et al., 1994; Hanabuchi et al., 1994; Stalder et
al., 1994), activation-induced T cell death (Dhein et al.,
1995; Ju et al., 1995; Brunner et al., 1995), regulation of ac-
tivated B cells by Th1 CD4
 
1
 
 T cells (Rothstein et al., 1995)
and liver damage (Ogasawara et al., 1993; Rensing-Ehl et
al., 1995; Galle et al., 1996).
The CD95 receptor (CD95) is expressed on a wide vari-
ety of normal and transformed cells (for review see Kram-
mer et al., 1994). Induction of apoptosis requires oligomer-
ization of the receptor on the cell surface either by CD95L
or agonistic monoclonal antibodies (mAb). Within sec-
onds after receptor oligomerization, an adaptor molecule,
FADD/MORT1, is found associated with the functional
receptor (Boldin et al., 1995; Chinnaiyan et al., 1995; Kisch-
kel et al., 1995). The death effector domain of FADD, in
turn, has been recently shown to interact with an ICE-
related protease (IRP) called FLICE/MACH1
 
a
 
 (Boldin et
al., 1996; Muzio et al., 1996) or caspase-8, according to the
new nomenclature proposed by Alnemri et al. (1996). Re-
cruitment of FLICE/MACH1
 
a
 
 to the signaling complex is
believed to lead to proteolytic activation of FLICE itself
and of other apoptosis-mediating IRPs /caspases, thereaf-
ter (Muzio et al., 1996). Sequential activation of ICE-like
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1. 
 
Abbreviations used in this paper
 
: Ab, antibody; CD95, CD95/APO-1/
Fas receptor; CD95L, CD95/APO-1/Fas ligand; CHO, aldehyde; cmk,
chloromethylketone; ICE, IL-1
 
b
 
 converting enzyme; IRP, ICE-related
protease; PARP, poly(ADP)-ribose polymerase; SN, supernatant.
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and CPP32-like proteases was found to occur in CD95-
mediated apoptosis (Enari et al., 1995; Chinnaiyan et al.,
1996; Duan et al., 1996).
The finding that among the TNF family members, TRAIL
and CD95L share the highest homology and show a simi-
lar potency in inducing apoptosis (Wiley et al., 1995),
raises the question of the extent of redundancy existing
between these two systems. To address this issue, we have
expressed and characterized recombinant mouse TRAIL
using the baculovirus expression system, as previously re-
ported for CD95L (Mariani et al., 1996). In the present
study we compare the target specificity and the intracellu-
lar pathway(s) activated by TRAIL and CD95L. We show
that mouse myeloma cells, that are resistant to CD95L, are
sensitive to TRAIL and that inhibition of IRPs/caspases
by synthetic peptides prevents all TRAIL-induced apop-
totic events analyzed: i.e., morphological changes, disorgani-
zation of plasma membrane phospholipids, poly(ADP)-
ribose polymerase (PARP) cleavage, DNA fragmentation,
and cell death.
 
Materials and Methods
 
Materials
 
The tetrapeptide chloromethylketone Acetyl-Tyr-Val-Ala-Asp-cmk (Ac-
YVAD-cmk) (an irreversible inhibitor of IRPs/caspases) and the tet-
rapeptide aldehyde Acetyl-Asp-Glu-Val-Asp-CHO (Ac-DEVD-CHO) (a
reversible inhibitor of IRPs/caspases) were obtained from Bachem (Switzer-
land). Stock solutions of peptide inhibitors (40 mM) were prepared in
DMSO and stored at 
 
2
 
80
 
8
 
C. Working solutions were made in culture me-
dium immediately before use. The recombinant mouse wild-type CD95L,
the mouse 
 
gld
 
 CD95L (Lynch et al., 1994; Takahashi et al., 1994) and the
human CD95L (Suda et al., 1993; Suda and Nagata, 1994) expressed in Sf9
cells (Mariani et al., 1996) as well as the anti-CD95L antibody have been
described previously (Mariani et al., 1995). The anti-PARP Ab was kindly
provided by A. Bürkle.
 
Cells
 
The CD95L-resistant mouse myeloma cells Ag8, the CD95L-sensitive hu-
man T leukemia cells Jurkat, the human B lymphoma cells, Bjab and
REH, and the mouse T hybridoma cells 2H11 were cultured in RPMI-
1640 medium supplemented with 10% heat-inactivated FCS, 100 U/ml
penicillin, 100 
 
m
 
g/ml streptomycin, 10 mM Hepes (pH 7.2) and 2 mM
glutamine at 37
 
8
 
C with 5% CO
 
2
 
 in a humidified atmosphere. The cell via-
bility was greater than 95% in each cell preparation used. Sf9 insect cells
were purchased from GIBCO BRL (Gaithersburg, MD) and cultured at
27
 
8
 
C in Grace’s insect medium (GIBCO BRL) supplemented with 10%
heat-inactivated FCS.
 
Preparation of Rabbit Anti-TRAIL Antibodies and 
Control Mouse mAb
 
Rabbit anti-TRAIL antibodies were developed as previously described
(Mariani et al., 1994, 1995) in accordance with institutional guidelines.
Briefly, the 21-mer peptide NEHLIDMDHEASFFGAFLVGC was con-
jugated to keyhole lympet hemocyanin (KLH) by 
 
m
 
-maleimidobenzoyl-
 
N
 
-hydroxysuccinimide ester (MBS) (Pierce, Rockford, IL) and mixed
with complete Freund’s adjuvant (CFA). Rabbits were immunized with
700 
 
m
 
g of the conjugated peptide. The animals were boosted at biweekly
intervals with half the dose of the same immunogen in incomplete Freund’s
adjuvant (IFA) and bled 7–8 d after each boost. Rabbit IgG was purified
by affinity chromatography on protein A–Sepharose (Pharmacia, Upp-
sala, Sweden) according to the manufacturer’s instructions. The hybrid-
oma secreting the mouse mAb SM 22 (IgG,k) was established from the
spleen of a mouse immunized with baculovirus-infected Sf9 cells. In im-
munoblots, it specifically recognizes baculovirus-derived proteins with an
apparent molecular mass of 27–32 kD. It does not react with non-infected
Sf9 cells or a variety of eukaryotic cells.
 
Cloning of Mouse TRAIL cDNA
 
Mouse TRAIL cDNA was synthesized by RT-PCR using the following
primers: 5
 
9
 
 sense: 5
 
9
 
 ATA CCC GGG GCC ACC ATG CCT TCC TCA
GGG GCC CTG AAG 3
 
9
 
 and 3
 
9
 
 antisense: CCT CGG AAA AAT TAA
TTG ATT CTT AAG ATA 5
 
9
 
. Sequences corresponding to TRAIL
cDNA are underlined. The cDNA was cloned into the baculovirus trans-
fer vector pVL1393 (Invitrogen, San Diego, CA) downstream from the
polyhedrin promoter according to standard protocols (O’Reilly et al.,
1994). The sequence of the cloned cDNA was confirmed by double strand
cDNA sequencing and found to be identical to that published (Wiley et
al., 1995).
 
Expression of Recombinant Mouse TRAIL in Sf9
Insect Cells
 
TRAIL was expressed as previously described for recombinant mouse
and human CD95L (Mariani et al., 1996). Sf9 insect cells were cotrans-
fected with TRAIL cDNA-containing transfer vector and linearized 
 
Au-
tographa californica
 
 nuclear polyhedrosis virus (AcNPV) DNA (Baculo-
Gold DNA, Pharmingen, San Diego, CA) according to the manufacturer’s
instructions. 4 d after transfection, supernatants containing the recombi-
nant virus were harvested from transfected cells and used to infect Sf9
cells that had been plated in 60-mm petri dishes at 2 
 
3
 
 10
 
6
 
 cells/dish. After
infection, the cell monolayer was overlaid with 1% Seaplaque agarose
(FMC BioProducts, Rockland, ME). Individual viral plaques were iso-
lated and tested for expression of TRAIL (O’Reilly et al., 1994). The titer
of the recombinant virus was determined by end-point dilution. The re-
combinant virus was further expanded to generate a stock virus by infect-
ing Sf9 cells at a multiplicity of infection (MOI) of 0.1. Infection of Sf9
cells for protein production was performed with an MOI of 10 (Summers
and Smith, 1987). Supernatants were collected 4 d after infection from cul-
ture flasks with a confluent monolayer of Sf9 cells, spun at 1,000 
 
g
 
 for 10
min and stored at 4
 
8
 
C. Cells were further washed with PBS and stored as
frozen pellets at 
 
2
 
80
 
8
 
C.
 
SDS-PAGE and Immunoblotting of
Recombinant TRAIL
 
SDS-PAGE and immunoblotting were performed as previously described
(Mariani et al., 1994). Briefly, following SDS-PAGE, proteins were trans-
ferred to nitrocellulose membranes by semi-dry electroblotting. Mem-
branes were blocked with 5% nonfat dry milk in PBS and then incubated
overnight with the primary antibody. Membranes were washed five times
with PBS/0.5% Tween 20 and incubated with HRPO-conjugated affinity-
purified mouse anti–rabbit IgG Ab or HRPO-conjugated affinity-purified
goat anti–mouse IgG Ab (Dianova, Hamburg, FRG) for 2 h. Membranes
were then washed five times and the reaction developed using the ECL
detection system (Amersham, Frankfurt, FRG).
 
Determination of Cell Death
 
Cell death was assessed as described previously (Darzynkiewicz et al.,
1992; Chrest et al., 1993; Mariani et al., 1996). Briefly, serial dilutions of
supernatants of Sf9 cells expressing mouse TRAIL or mouse wild-type
and 
 
gld
 
 CD95L were incubated with target cells overnight in 96-well mi-
crotiter plates. Cell death was determined by forward/side scatter analysis
and PI staining using a FACScan (Becton Dickinson, Heidelberg, FRG).
The target cells were the mouse myeloma cells Ag8, the human CD95L-
sensitive T lymphoblastoid cells Jurkat, and the mouse T hybridoma cells
2H11. Blocking and control reagents were added to the plates immedi-
ately before addition of the target cells. Results are expressed as percent
specific cell death calculated according to the formula: (Experimental 
 
2
 
Background)/(100 
 
2
 
 Background) 
 
3 
 
100. Background apoptosis was mea-
sured in target cells incubated with serial dilutions of Sf9 culture medium.
 
MC540 Staining and Flow Cytometry
 
MC540 staining was performed as previously described (Fadok et al., 1992).
Briefly, cells incubated with recombinant TRAIL or CD95L were stained
with the dye Merocyanine 540 (MC540), freshly diluted in PBS (5 
 
m
 
g/ml),
a few minutes before analysis. Uptake of MC540 was determined by flow
cytometric analysis. Cells undergoing loss of physiological asymmetry in
plasma membrane phospholipids expose phosphatidylserine residues with
a high uptake of MC540. Results are expressed as percent cells with high 
Mariani et al. 
 
Caspases in TRAIL-induced Apoptosis
 
223
 
MC540 uptake. The morphology of cells undergoing TRAIL- and
CD95L-mediated apoptosis was not affected by MC540 staining.
 
DNA Fragmentation
 
DNA fragmentation was analyzed as previously described (Wyllie and
Morris 1982; Mariani et al., 1996). Briefly, target cells incubated with re-
combinant TRAIL or CD95L were washed and lysed for 30 min at 4
 
8
 
C in
hypotonic buffer (10 mM Tris, pH 7.5, 1 mM EDTA, 0.2% Triton X-100).
Lysates were centrifuged at 13,000 
 
g
 
 for 10 min. Soluble fragmented DNA
was precipitated overnight from the supernatant by adding 0.5 M NaCl
and an equal volume of isopropanol. The precipitated DNA was recov-
ered by centrifugation at 13,000 
 
g
 
 for 15 min, dissolved in TE (10 mM Tris,
pH 7.4, 1 mM EDTA) and electrophoresed on a 1% agarose gel at 10 V/
cm. DNA bands were visualized by ethidium bromide staining and digi-
tized by high resolution optical scanning; volumetric integration of signal
intensities was performed using the Scan Analysis software. Results are
expressed as relative density units.
 
Results
 
Expression of Recombinant Mouse TRAIL and 
Generation of Rabbit Anti-TRAIL Antibodies
 
To produce functional recombinant TRAIL, full-length
mouse TRAIL cDNA was subcloned into the baculovirus
expression vector pVL1393 under the strong polyhedrin
promoter. Sf9 cells were infected with the recombinant vi-
rus and tested for expression of recombinant TRAIL. To
specifically detect TRAIL, a rabbit polyclonal antibody was
developed in rabbits immunized with a peptide correspond-
ing to the carboxy-terminal region of TRAIL. As shown in
Fig. 1 
 
A
 
, the Ab specifically detects a protein of 
 
z
 
32–33
kD in lysates of Sf9 cells expressing TRAIL (lane 
 
1
 
) but
not of Sf9 cells expressing CD95L (lane 
 
2
 
). No reactivity
was found in both cell lysates with purified rabbit IgG. In-
cubation of the same cell lysates with the mouse mAb SM22
to a baculovirus-derived product showed an equal loading
of cell extract (Fig. 1 
 
B
 
).
Immunoblot analysis of the supernatant (SN) of in-
fected Sf9 cells showed that during the lytic infection, re-
combinant TRAIL is released into the culture medium
(Fig. 1 
 
C
 
, lane 
 
2
 
). The apparent molecular weight, deter-
mined by SDS-PAGE under reducing conditions, suggests
that TRAIL present in the SN is similar to the membrane-
bound form present in Sf9 cells (Fig. 1 
 
A
 
) and in Sf9 mem-
brane preparations (not shown). A similar phenomenon was
observed for recombinant mouse and human CD95L pro-
duced in the same expression system (Mariani et al., 1996).
 
Differential Sensitivity of the Mouse Myeloma Cells 
Ag8 to TRAIL and CD95L
 
Recombinant TRAIL was tested for functional activity by
incubating SN from TRAIL-expressing Sf9 cells with the
human leukemic cells Jurkat. TRAIL killed the target cells
but no cell death was observed in Jurkat cells incubated
with control medium or SN of Sf9 cells expressing mouse
 
gld
 
 CD95L. (Fig. 2 
 
A
 
). To assess the ability of recombinant
TRAIL to affect mouse cells, a similar assay was per-
formed with the mouse myeloma cells Ag8 as target. As
shown in Fig. 2 
 
B
 
, Ag8 cells were killed very efficiently by
TRAIL but not by the control mouse 
 
gld
 
 CD95L. It is of
note that the same target cells were almost completely re-
sistant to recombinant mouse and human CD95L. Speci-
ficity was further indicated by the lack of cell death in T
hybridoma cells incubated with mouse TRAIL and CD95L
(Fig. 3 
 
A
 
).
 
Features of Apoptosis Induced by TRAIL in Myeloma 
and Leukemia Cells
 
To characterize the cell death induced by TRAIL, mor-
phology, DNA integrity, and membrane lipid organization
of target cells were examined. Ag8 cells exposed to TRAIL
showed membrane blebbing, reduction in cell size, increase
in surface rugosity (increase in side scatter) (Fig. 3 
 
A
 
), nu-
clear condensation, and release of apoptotic bodies (not
shown). Similar events were seen also in Jurkat target
cells, as previously described (Wiley et al., 1995). Analysis
of soluble DNA from the target cells showed that a signifi-
cant quantity of fragmented DNA was present in the cyto-
plasm of target Ag8 (lane 
 
3
 
) and Jurkat cells (lane 
 
6
 
) incu-
Figure 1. Immunoblot analysis of recombinant mouse TRAIL.
(A) Whole cell lysates of Sf9 cells expressing recombinant mouse
TRAIL (lane 1) or mouse CD95L (lane 2) were tested with puri-
fied rabbit anti-TRAIL Ab. Molecular weight markers are indi-
cated. HRPO-labeled mouse anti–rabbit IgG antibodies were
used as the detecting reagent. No reactivity was present with pu-
rified rabbit IgG. (B) Whole cell lysates of Sf9 cells expressing re-
combinant mouse TRAIL (lane 1) or mouse CD95L (lane 2) and
cell lysates of non-infected Sf9 cells (lane 3) were tested with the
mouse mAb SM22 to a baculovirus-related product. Molecular
weight markers are indicated. HRPO-labeled rabbit anti–mouse
IgG antibodies were used as the detecting reagent. No reactivity
was present with an isotype-matched control mAb. (C) SN of Sf9
cells expressing mouse TRAIL (lane 2) or mouse CD95L (lane 1)
were tested with purified rabbit anti-TRAIL antibody. Molecular
weight markers are indicated. HRPO-labeled mouse anti–rabbit
IgG antibodies were used as the detecting reagent. No reactivity
was found with purified rabbit IgG. 
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bated for 6 h with TRAIL (Fig. 3 
 
B
 
). Specificity is indicated
by the lack of oligonucleosomal DNA fragments in ex-
tracts of Ag8 cells incubated with CD95L (lane 
 
2
 
) and of T
hybridoma cells incubated with both ligands (not shown).
It is of note that the pattern of TRAIL-induced DNA frag-
mentation is different between Ag8 and Jurkat cells. As
shown in lanes 
 
5
 
 and 
 
6
 
, the same pattern of DNA fragmen-
tation is present in Jurkat cells undergoing TRAIL- or
CD95L-mediated apoptosis. Thus, the phenotypic differ-
ence in the average size of the DNA fragments between
Ag8 and Jurkat cells, seems to be independent of the ef-
fector molecule and the extent of apoptosis. It may reflect
the activation of different nucleases and/or a different sus-
ceptibility of cellular DNA to enzymatic fragmentation.
Distribution of phospholipids in the cellular plasma
membranes was determined by MC540 staining (Fadok et
al., 1992). As shown in Fig. 4 
 
A
 
, incubation of Jurkat cells
with increasing concentrations of TRAIL, led to an in-
creasingly higher uptake of MC540, suggesting an alter-
ation of the membrane lipids and increased exposure of
phosphatidylserine, as previously described for other apop-
tosis-inducing agents (Martin et al., 1995). Similar results
were obtained with Ag8 cells (not shown). Specificity is in-
dicated by the lack of increased MC540 uptake by Jurkat
cells incubated with mouse 
 
gld
 
 CD95L (Fig. 4 
 
A
 
). Higher
uptake of MC540 was correlated with the apoptotic phe-
notype of the target cells. As shown in Fig. 4 
 
B
 
, only the
apoptotic cells undergoing shrinkage and increase in sur-
face rugosity (gate R2) showed increased uptake of
MC540. A kinetic analysis indicated that high uptake of
MC540 by target cells preceded loss of cell viability as de-
termined by propidium iodide permeability (not shown).
These results indicate that TRAIL-induced apoptosis is
associated with loss of membrane phospholipid asymme-
try not only in normal T cells (Marsters et al., 1996) but
also in T cells with a transformed phenotype.
 
The IRP/Caspase-Inhibitors Ac-YVAD-cmk,
and Ac-DEVD-CHO Block the Morphological and 
Structural Changes Associated with TRAIL-induced 
Apoptosis in Myeloma and Leukemia Cells
 
To assess if IRPs/caspases are involved in the intracellular
Figure 2. Target cells resistant to mouse CD95L are sensitive to
mouse TRAIL. CD95L-sensitive human leukemia Jurkat cells
(Jurkat) (A) and CD95L-resistant mouse myeloma cells Ag8 (Ag8)
(B) were incubated overnight with SN from Sf9 cells expressing
mouse gld CD95L (gld CD95L), mouse TRAIL (TRAIL), mouse
wild-type CD95L (mCD95L), and human CD95L (hCD95L). Re-
sults are expressed as percent specific cell death. Background apop-
tosis of the target cells incubated with SN of mock-infected Sf9
cells was ,15%.
Figure 3. Induction of apoptosis and DNA fragmentation in Ag8
cells by recombinant mouse TRAIL. (A) The human T leukemia
cells Jurkat (Jurkat) (left panels), the mouse myeloma cells Ag8
(Ag8) (central panels), and the mouse T hybridoma cells 2H11
(TcHy) (right panels) were incubated with SN from Sf9 cells ex-
pressing mouse TRAIL (TRAIL) (upper panels), or mouse wild-
type CD95L (CD95L) (lower panels). Results are presented as
forward/side scatter analysis of cellular morphology. Apoptotic
cells are shown in gate R1. (B) Soluble DNA was extracted from
Ag8 (Ag8) (lanes 1–3) and Jurkat cells (Jurkat) (lanes 4–6) (0.5 3
106 cells/lane) incubated with SN from mock-infected Sf9 (lanes 1
and 4) or from Sf9 cells expressing mouse CD95L (lanes 2 and 5)
or mouse TRAIL (lanes 3 and 6). Extracted DNA was separated
on an agarose gel and visualized by ethidium bromide staining.
Molecular mass markers (MM) are shown. No soluble DNA was
extracted from TRAIL-resistant T hybridoma cells incubated
with either ligand. 
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signaling events triggered by TRAIL receptor engage-
ment, peptide inhibition experiments were performed. The
mouse myeloma cells Ag8 exposed to TRAIL in the pres-
ence of the synthetic peptide Ac-YVAD-cmk did not un-
dergo the morphological changes characteristic of TRAIL-
mediated apoptosis, i.e., membrane blebbing and nuclear
condensation, as determined by optical microscopy. The
lack of cell shrinkage and of increased cellular density are
presented in the forward/side scatter analysis of Fig. 5 
 
A.
 
Equal concentrations of the vehicle (dmso) did not pre-
vent TRAIL-induced cell death. Very similar results were
obtained with the peptide Ac-DEVD-CHO (not shown).
Analysis of the dose-effect relationship (Fig. 5 
 
B
 
) showed
that maximal inhibition was achieved at a concentration of
200 
 
m
 
M of Ac-YVAD-cmk, with an IC50 (concentration
yielding 50% inhibition) of 
 
z
 
50 
 
m
 
M. Very similar results
were obtained when the human leukemic cells Jurkat were
used as target. In these cells, the Ac-YVAD-cmk peptide
blocked TRAIL-induced apoptosis with an IC50 of z75
mM (Fig. 6 A). To determine whether Ac-YVAD-cmk
could prevent loss of asymmetry in the plasma membrane
phospholipids, exposure of phosphatidylserine residues
was determined in target cells by measuring uptake of the
lipophilic dye MC540 (Fadok et al., 1992). As shown in
Fig. 6 B Jurkat cells exposed to TRAIL in the presence of
increasing concentrations of Ac-YVAD-cmk displayed a
dose-dependent inhibition of the TRAIL-induced alter-
ation in plasma membrane phospholipids. Similar results
were obtained with Ag8 cells as target or with Ac-DEVD-
CHO as inhibitor (not shown).
The nuclear repair enzyme PARP is cleaved by IRPs/
caspases during apoptosis induced by CD95 receptor trig-
gering (Tewari et al., 1995) and by a variety of other agents
(Henkart, 1996). To determine whether PARP is cleaved
in cells undergoing TRAIL-mediated apoptosis, immuno-
blotting experiments were performed. As shown in Fig. 7,
PARP (z116 kD) was cleaved in sensitive Jurkat (lane 2)
and Bjab cells (lane 6) with generation of a shorter frag-
ment of z85 kD following incubation with TRAIL. Speci-
ficity is indicated by the lack of PARP cleavage in Jurkat
(lane 1) and Bjab cells (lane 5) incubated with SN of
Figure 4. Induction of plasma membrane phospholipid disorgani-
zation by recombinant mouse TRAIL. The T leukemia cells Jur-
kat were incubated overnight with serial dilutions of SN from Sf9
cells expressing mouse TRAIL (filled circles) or mouse gld CD95L
(empty squares). Results are expressed as percent cells with high
uptake of the lipophilic dye MC540 (A). In B, results are pre-
sented as forward/side scatter analysis of cells incubated with re-
combinant TRAIL. MC540 uptake is shown for cells with non-
apoptotic morphology (gate R1) (white histogram) and for cells
with apoptotic morphology (gate R2) (gray histogram). No differ-
ence in cell morphology was observed in Jurkat cells exposed to
TRAIL in the presence or absence of MC540.
Figure 5. The IRP/caspase-inhibitor Ac-YVAD-cmk blocks TRAIL-
induced apoptosis in mouse myeloma cells. (A) The mouse my-
eloma cells Ag8 were incubated overnight with SN of Sf9 cells ex-
pressing mouse TRAIL (central and right panel) in the presence
of the peptide inhibitor Ac-YVAD-cmk (200 mM) (right panel)
or an equal concentration of vehicle (dmso) (central panel). As a
specificity control Ag8 cells were incubated with SN of mock-
infected Sf9 cells (left panel). Results are presented as forward/
side scatter analysis of cellular morphology. Apoptotic cells are
shown in gate R1. (B) Ag8 cells were incubated overnight with
SN of Sf9 cells expressing mouse TRAIL in the presence of in-
creasing concentrations of the peptide inhibitor Ac-YVAD-cmk
(squares). Equal concentrations of vehicle (triangles) were used
as a specificity control. Results are expressed as percent specific
cell death. Background apoptosis of target cells was ,15%.The Journal of Cell Biology, Volume 137, 1997 226
mock-infected Sf9 cells and in TRAIL-resistant REH cells
(lane 4). Triggering of TRAIL receptor in the presence of
the peptide inhibitor Ac-DEVD-CHO completely blocked
generation of the shorter fragment in Jurkat (lane 3) and
Bjab cells (not shown). No inhibition was present with the
vehicle alone. Thus, Ac-DEVD-CHO-inhibitable proteases
are involved in TRAIL-induced cleavage of PARP in sen-
sitive cells.
As shown previously, TRAIL-induced apoptosis is asso-
ciated with extensive fragmentation of cellular DNA. To
define the functional involvement of IRPs/caspases in this
process, inhibition experiments were performed with the
peptide inhibitors. As shown in Fig. 8, TRAIL-induced
fragmentation of DNA from Ag8 and Jurkat cells was
completely prevented in the presence of the IRP/caspase-
inhibitor Ac-DEVD-CHO (lanes 4 and 8). No difference
in the DNA fragmentation pattern or intensity was found
in the presence or absence of the vehicle (not shown).
Also the IRP/caspase inhibitor Ac-YVAD-cmk prevented
TRAIL-induced DNA fragmentation in both cell types,
but to a lower extent than the Ac-DEVD-CHO inhibitor
in Ag8 cells. These results indicate that Ac-YVAD-cmk-
and Ac-DEVD-CHO-sensitive IRPs/caspases are involved
in TRAIL-induced DNA fragmentation and apoptosis of
sensitive human and mouse cells.
Discussion
In the present study, we have compared the apoptotic re-
sponses induced by TRAIL and CD95L, which share the
highest degree of homology among the members of the
TNF family so far characterized (Wiley et al., 1995). Mouse
myeloma cells that are quite resistant to mouse CD95L
show a high sensitivity to recombinant mouse TRAIL. The
morphological and structural changes observed are very
similar to those displayed by CD95L-sensitive Jurkat cells
exposed to TRAIL or CD95L. The differential sensitivity
to CD95L and TRAIL, however, is not uniquely found in
mouse Ag8 cells, since also the mouse fibrosarcoma cells
L929 and the human T lymphoma cells HPB were found
to be sensitive to TRAIL- but not CD95L-mediated apop-
tosis. TRAIL function(s), therefore, seem to complement
the activity of the CD95 system allowing a wider variety of
cells to be sensitive to apoptosis triggered by specific ex-
tracellular ligands. The extent of the functional diversifica-
tion of the two systems will be more defined after detailed
analysis of a larger panel of normal and transformed cell
types.
The different effector potential of TRAIL and CD95L
may reflect differences in the proximal signaling complexes
(receptor and receptor-associated molecules) or in the more
downstream signaling pathway(s). IRPs/caspases were shown
to be the major mediators of intracellular proteolysis
which leads to the apoptotic demise of target cells exposed
to a variety of apoptosis-inducing agents (for review see
Martin and Green, 1995; Fraser and Evan, 1996; Henkart,
1996; Takahashi and Earnshaw, 1996). Different intracel-
lular proteins were found to be proteolytically cleaved dur-
ing CD95-mediated apoptosis. It is still not clear, however,
which are the critical targets that determine the irreversibil-
ity of the apoptotic response (Ashkenas and Werb, 1996).
The proteolytic cascade activated by CD95- and TNF-RI-
triggering can be blocked by crmA, a serpin-like molecule
(Tewari and Dixit, 1995) and by synthetic peptides that
represent specific target sequences of ICE and/or other
Figure 6. The IRP/caspase-inhibitor Ac-YVAD-cmk blocks TRAIL-
induced apoptosis in human leukemia cells. (A) The human leu-
kemia cells Jurkat were incubated overnight with SN of Sf9 cells
expressing mouse TRAIL in the presence of increasing concen-
trations of the peptide inhibitor Ac-YVAD-cmk (circles). Equal
concentrations of vehicle (squares) were used as a specificity con-
trol. Results are expressed as percent specific cell death. Back-
ground apoptosis of target cells was less than 15%. (B) Jurkat
cells were incubated for 8 h with SN of Sf9 cells expressing mouse
TRAIL in the presence of increasing concentrations of the pep-
tide inhibitor Ac-YVAD-cmk (circles). Equal concentrations of
vehicle (squares) were used as a specificity control. Results are
expressed as percent of cells with high uptake of the MC540 dye.
Figure 7. The IRP/caspase inhibitor Ac-DEVD-CHO blocks
TRAIL-induced PARP cleavage. Whole cell lysates of Jurkat
cells incubated with SN of Sf9 cells expressing mouse TRAIL
(lanes 2–3) or of mock-infected Sf9 cells (lane 1) in the presence
(lane 3) or absence of Ac-DEVD-CHO (lanes 1–2) were tested
with the anti-PARP Ab. The TRAIL-resistant REH (lane 4) and
the TRAIL-sensitive BJAB cells (lanes 5–6) incubated with
(lanes  4 and 6) or without TRAIL (lane 5) were used as specific-
ity controls. Molecular markers are indicated. HRPO-labeled
goat anti–mouse IgG Ab were used as the detecting reagent.Mariani et al. Caspases in TRAIL-induced Apoptosis 227
IRPs/caspases, Acetyl-Tyr-Val-Ala-Asp-cmk (Ac-YVAD-
cmk), and Acetyl-Asp-Glu-Val-Asp-aldehyde (Ac-DEVD-
CHO) (Enari et al., 1995; Los et al., 1995). ICE (caspase-1),
FLICE/MACH1a (caspase-8), Mch3/ICE-LAP3/CMH-1
(caspase-7), and CPP32/YAMA (caspase-3) were shown, so
far, to be the major intracellular effectors of CD95- and
TNF-mediated apoptotic signals (Enari et al., 1995; Kuida
et al., 1995; Los et al., 1995; Boldin et al., 1996; Chinnaiyan
et al., 1996; Duan et al., 1996; Enari et al., 1996; Muzio et
al., 1996).
Here, we provide evidence that similarly to CD95L, in-
tracellular signaling following TRAIL receptor engage-
ment, involves an IRP/caspase pathway. Dissociation of
TRAIL- from CD95L-sensitivity seems therefore to map
quite near to the receptor complexes. Inhibition of IRPs/
caspases was found to prevent all apoptotic events ana-
lyzed: (1) membrane blebbing, (2) cell shrinking, (3) disor-
ganization of plasma membrane phospholipids, (4) PARP
cleavage, (5) DNA fragmentation, and (6) cell death. These
findings are consistent with the observation that transfec-
tion with CrmA of TRAIL-sensitive B lymphoma cells
(Mariani, S., unpublished observations) or Hela cells
(Marsters et al., 1996) confers almost complete protection
from TRAIL-induced apoptosis. The concentrations of
peptide inhibitors required to block TRAIL-mediated apop-
tosis are very similar to those described in CD95L-induced
apoptosis for the Ac-YVAD-cmk inhibitor (Enari et al.,
1995) and in camptothecin-induced apoptosis for the Ac-
DEVD-CHO inhibitor (Nicholson et al., 1995). It is of note
that both Ac-YVAD-cmk- and Ac-DEVD-CHO-inhibitable
IRPs/caspases are involved in the apoptotic response trig-
gered by TRAIL in mouse myeloma and human leukemia
cells. The presence of PARP cleavage in cells undergoing
TRAIL-induced apoptosis suggests an active role for CPP32-
like proteases (Lazebnick et al., 1994; Fernandes-Alnemri
et al., 1995; Nicholson et al., 1995; Duan et al., 1996; Lippke
et al., 1996) as previously shown for CD95-mediated apop-
tosis (Tewari et al., 1995). It remains to be defined which
are the critical IRPs/caspases involved and whether there
is a cellular and/or a receptor specificity for any of them.
We have shown here that mouse myeloma cells are
quite resistant to CD95L. Similarly to other cell types, Ag8
cells express CD95 on their surface (Mariani et al., 1994),
and develop sensitivity after sensitization with protein syn-
thesis inhibitors (Mariani, S., unpublished results). It is
still not clear which are the cellular mechanisms that un-
derly this phenotypic conversion. They seem, however, to
reside in the signaling cascade proximal to the receptor, as
we have shown that Ag8 cells display a high sensitivity to
TRAIL and therefore possess an apparently intact down-
stream proteolytic cascade. It cannot, however, be ex-
cluded that distal events, i.e., negative regulators of the
proteolytic cascade, are unique to each receptor system
and are specifically released by cycloheximide in the pres-
ence of CD95L. Similarly to Ag8 cells, also the mouse my-
eloma cells J558L were shown to be resistant to CD95-
mediated apoptosis (Onel et al., 1995). In the human sys-
tem, two out of five myelomas (U266 and Hs) were found
to be resistant even though they expressed CD95 on their
surface. Similar results were reported for tumor cells
freshly isolated from myeloma patients (Shima et al.,
1995). The mechanisms underlying resistance to CD95-
triggering and potential sensitization to CD95-mediated
apoptosis by cycloheximide were not addressed in these
studies. From a practical point of view, the finding that
myeloma cells are very sensitive to TRAIL suggests that
development of agonistic mAbs to the mouse TRAIL re-
ceptor, still to be characterized, may be a tricky endeavor.
Availability of a TRAIL-resistant myeloma variant for cell
fusion may help to overcome this problem.
While much attention is focused on the biological func-
tions of the CD95 system, no information is available, at
present, on the physiological relevance of the TRAIL sys-
tem. Availability of recombinant TRAIL described here
will help in elucidating its function(s). In this study we
have employed a membrane-like form of recombinant
mouse TRAIL. We have shown previously that Sf9 cells
Figure 8. The Ac-YVAD-cmk and Ac-DEVD-CHO peptide in-
hibitors block TRAIL-induced DNA fragmentation in mouse
and human cells. (A) Soluble DNA was extracted from mouse
myeloma cells Ag8 (lanes 1–4) (Ag8) or from the human leuke-
mia cells Jurkat (lanes 5–8) (Jurkat) (0.5 3 106 cells/lane) incu-
bated with SN from mock-infected Sf9 (lanes 1 and 5) or with SN
from TRAIL-expressing Sf9 cells (lanes 2–4 and 6–8) in the pres-
ence of the peptide inhibitor Ac-YVAD-cmk (lanes 3 and 7) or
Ac-DEVD-CHO (lanes 4 and 8) (200 mM). An equal concentra-
tion of vehicle (dmso) was used as a specificity control (lanes 2
and 6). Extracted DNA was separated on an agarose gel and visu-
alized by ethidium bromide staining. Molecular mass markers
(MM) are shown. In B, results are shown as relative density of
fragmented DNA in each lane (relative density units) as deter-
mined by densitometric analysis.The Journal of Cell Biology, Volume 137, 1997 228
lytically infected with recombinant virus release functional
mouse and human CD95L in the culture medium, respec-
tively (Mariani et al., 1996). These ligands, with a relative
molecular weight similar to that of the membrane-bound
form, were found to be associated with small membrane
vescicles, thus mimicking the physiological expression of
membrane-bound CD95L. A very similar phenomenon is
observed here for recombinant mouse TRAIL. So far, re-
combinant TRAIL has been stably expressed only as a sol-
uble form. Wiley et al. (1995) showed that purified soluble
TRAIL has a low effector activity. Cross-linking with an
anti-FLAG mAb led to an z30-fold increase in cytotoxic
activity. Marster et al. (1996), on the other hand, prepared
a His-tagged soluble human TRAIL that was used at very
high concentrations (1 mg/ml), considering the specific ac-
tivity of 10 and 6.5 3 106 U/mg estimated for TNF and
CD95L, respectively (Suda et al., 1994). These data would
suggest that oligomerization of TRAIL is required for ef-
fective triggering of its receptors, as previously found for
the CD95 system (Krammer et al., 1994; Peitsch and
Tschopp, 1995). Since recombinant mouse TRAIL, pro-
duced by Sf9 cells seems to have the characteristics of a
membrane-associated protein, it may represent a useful
source of functional TRAIL with a more physiological in-
teraction at the receptor level. It remains, in fact, to be es-
tablished whether TRAIL is released physiologically as a
soluble mediator from mouse and human cells, as previ-
ously described for human CD95L (Mariani et al., 1995;
Tanaka et al., 1995).
Our finding that IRPs/caspases are involved in TRAIL-
induced apoptosis underlines the critical role played by
this family of proteolytic enzymes, as they appear to medi-
ate almost every known form of apoptosis (Henkart,
1996). For therapy (Enari et al., 1995; Nicholson et al.,
1995; Thornberry et al., 1995; Rouquet et al., 1996) this
could imply an excessive nonspecificity with the risk of a
generalized block of apoptosis. More selective strategies
will have to be devised, if a specific block of only one
ligand/receptor system is desired: i.e., inhibitors targeted
at the ligand/receptor interaction, at the proteins associ-
ated with the proximal signaling complexes and/or at spe-
cific IRPs/caspases with potentially unique selectivity.
We thank A. Hekele and J.P. Medema for critical reading of the manu-
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